FIGURE 4.

Efficacy and safety for treatment regimens for the whole population. Pooled estimates of the network meta‐analysis. Hazard ratios less than 1 and odds ratios more than 1 favor the former treatment. Significant results are in bold. We did not show the analysis results for Beva + Chemo and Chemo. Atezo + Beva + Chemo, Atezolizumab + Bevacizumab + Chemotherapy; Carem + Chemo, Camrelizumab + Chemotherapy; Ipi + Chemo, Ipilimumab + Chemotherapy; Nivo + Beva + Chemo, Nivolumab + Bevacizumab + Chemotherapy; Nivo + Ipi, Nivolumab + Ipilimumab; Nivo + Ipi + Chemo, Nivolumab + Ipilimumab + Chemotherapy; Pembro + Chemo, Pembrolizumab + Chemotherapy; Tisle + Chemo, Tislelizumab + Chemotherapy